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Summary
The HER family of receptors has an important role in the
network of cell signals controlling cell growth and differentia-
tion. Although the activity of the HER receptor is strictly
controlled in normal cells, HER2 receptor overexpression
plays a pivotal role in transformation and tumorigenesis.
HER2 gene amplification and/or overexpression of the receptor
has been detected in subsets of a wide range of human cancers
including breast cancer, and is an indicator of poor prognosis.
It is proposed that overexpressed HER2 in combination with
HER3 causes high activity of cell-signaling networks, thereby
resulting in tumor cell proliferation. Thus, the HER2 receptor
is an attractive target for new anti-cancer treatments. Mono-
clonal antibodies directed against the receptor are the most
promising of these, and the humanized anti-HER2 monoclonal
antibody trastuzumab (Herceptin) has shown significant clin-
ical efficacy in clinical trials. The anti-tumor mechanisms of
anti-HER2 monoclonal antibodies are not completely under-
stood. However, some tumor types are not sensitive to trastu-
zumab, suggesting that the response of a tumor to trastuzumab
may not only be dependent on overexpressed HER2, but may
also be influenced by other members of the HER receptor
family expressed in the tumor cell.
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The HER2 receptor as a target for cancer treatment
The HER family of human epidermal growth factor
receptors consists of four members: HER1, HER2,
HER3 and HER4. The transmembrane HER receptors
have important roles in the network of cell signals con-
trolling cell growth and differentiation. In a normal cell,
the activity of the receptors is strictly controlled, most
significantly through the HER2 receptor [1].
In vitro and animal studies have clearly indicated that
HER2 protein overexpression plays a pivotal role in
oncogenic transformation and tumorigenesis. Studies
using NIH 3T3 cells implicate HER2 overexpression in
malignant transformation and tumorigenesis [2-4].
Transfection of the HER2 gene into human breast and
ovarian tumor cell lines produced more aggressive
growth characteristics, such as increased DNA synthesis,
cell growth, growth in soft agar in vitro, and tumori-
genicity and metastatic potential in mice [5, 6].
HER2 gene amplification and/or overexpression of
the receptor has been detected in subsets of a wide range
of human cancers, including breast cancer [7—11]. The
significance of HER2 amplification and HER2 over-
expression have been studied most widely in breast
cancer; around 20% of breast tumors overexpress HER2.
Slamon et al. [12] first observed that HER2-gene amplifi-
cation independently predicted overall (OS) and disease-
free survival (DFS), and many studies have confirmed
that HER2 overexpression is an indicator of poor prog-
nosis in women with breast cancer. These patients have
poor response rates and short DFS and OS compared
with women whose tumors do not overexpress this
receptor.
The HER2 receptor is being investigated as a target
for new more effective anti-cancer treatments. Its acces-
sible location on the cell surface makes it particularly
attractive. A number of approaches are being devel-
oped, including tyrosine kinase inhibitors, anti-sense
approaches which downregulate expression of the HER2
gene, intracellular expression of single-chain antibodies
(ScFvs) to functionally inactivate the receptor, and
immunization to boost anti-HER2 responses. The growth
of tumors and human breast cancer cell lines over-
expressing the HER2 receptor is also inhibited by
monoclonal antibodies directed at the extracellular
domain of the receptor [13, 14]. The humanized anti-
HER2 monoclonal antibody trastuzumab (Herceptin)
has shown significant clinical efficacy in trials of women
with breast cancer who have not responded to or who
have relapsed after previous treatment with chemo-
therapy.
Our laboratory has tried to identify how overexpressed
HER2 is involved in the transformation of cells in
tumors. Understanding this mechanism will help clarify
the mechanism of action of the monoclonal antibodies
and allow this promising new treatment to be opti-
mized.
Overexpression of HER2 receptors
The HER2 protein is encoded by the HER2 gene and
amplification of this gene appears to be the most common
mechanism leading to HER2 protein overexpression.
Overexpression is displayed by 10%—30% of breast,
ovarian and gastric cancers [15] and the highest frequency
of overexpression, approximately 60%, is found in ductal
carcinoma in situ [15]. However, overexpression is not
always a result of amplification. In some tumors, it has
therefore been suggested that HER2 protein overexpres-
sion may result from transcriptional or post-transcrip-
tional dysregulation [10]. Lung mesenchymal, bladder
and esophageal tumors are included in this category.
The structure of overexpressed HER2 protein appears
to be the same as that found in normal healthy cells,
since no mutational changes in the HER2 gene product
have been identified in human cancers [16].
The usual sequence of oncogenic transformation
appears to result from initial HER2 gene amplification,
which generates more than the two normal gene copies
in the epithelial cell; more than 10 gene copies are
usually seen in the amplified state [17-19]. The specific
factors that induce amplification of the HER2 gene have
yet to be fully elucidated [20]. HER2 gene amplification
leads to increased transcription of the HER2 gene, which
gives rise to increased HER2 mRNA levels and con-
comitant increased synthesis of HER2 protein. HER2
protein is then consequently overexpressed on the cell
surface. HER2 protein levels are about 10- to 100-fold
greater on the cell surface of HER2-positive breast
cancer cells compared with adjacent normal breast epi-
thelial cells [21].
Overexpression of HER2 protein on the cell surface
probably leads to constitutive activation of HER2 homo-
dimer receptors without the need for ligand binding.
This results in unregulated cell growth and oncogenic
transformation, in some instances resulting in viable
cancer. As a result of spontaneous formation of receptor
dimers, HER2 has a high basal activity in tumors in
which it is overexpressed, which may affect the activity
and/or expression of other HER family members. The
finding that HER3 has elevated levels of phosphotyro-
sine in HER2-positive tumors implies that HER2
contributes to malignant growth by recruiting other
HER receptors, particularly HER3.
HER2 and cell transformation
In order to elucidate the role of overexpressed HER2 in
transformation of cells, HER2 in_SjU3r3_t>reast tumor
cells was functionally inactivated via inducible expres-
sion of a HER2-directed ScFv5R [22, 23]. The HER2
receptor is normally expressed on the cell membrane. In
cells expressing the ScFv5R, the HER2 receptor binds
the single chain antibody in the endoplasmic reticulum
leading to its retention in that compartment and
functional inactivation of the receptor. In HER2-over-
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Figure I. Model of oncogenic HER2-dependent proliferation.
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Figure 2. Cell cycle control in the normal cell (for explanation see text).
expressing SKBr3 cells induction of ScFv5R expression
leads to loss of plasma membrane localized HER2.
Simultaneously, the signaling activity of HER3, as
measured by phosphotyrosine content, MAP kinase and
PKB, decreased dramatically suggesting that active
HER2/HER3 dimers are necessary for signal transduc-
tion. HER3 is one of the most important cytoplasmic
effectors of HER2, but is 'kinase dead' due to substitu-
tions in important residues in the kinase domain. Thus,
HER3 requires heterodimerization with another member
of the HER family, usually HER2, to exert its cell-
signaling action. It is proposed that overexpressed HER2
in combination with HER3 causes high activity of sig-
naling pathways which results in uncontrolled cyclin
E/Cdk2 activity. Thus, HER2 and HER3 function
together to stimulate signaling networks that result in
tumor cell proliferation (Figure 1) [24].
Loss of HER2 from the plasma membrane caused the
SKBr3 cells to accumulate in the Gl phase of the cell
cycle and the cells ceased proliferating after three days
of ScFv5R induction [24]. Cell cycling and homeostasis
in normal cells is maintained via an interacting network
of cytoplasmic signaling molecules and nuclear cell cycle
regulators (Figure 2). These regulators include the
nuclear cyclins and their associated kinases, the cyclin-
dependent kinases (Cdks) which control normal pro-
gression through the cell cycle. An important regulator
of Gl is Cdk2, which is positively regulated by associa-
tion with cyclin E and is negatively regulated by various
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Figure 3. Model of p27 regulation. X, one of a range of molecules with which p27 can form complexes (for explanation see text).
mechanisms including binding with the cyclin kinase
inhibitor p27. Regulation of p27 involves a number of
steps (Figure 3). p27 exists in numerous complexes; in
particular it is sequestered from cyclin E/Cdk2 by asso-
ciation with the D type cyclin complexes. Downregula-
tion and functional inactivation of HER2 after 72 hours
of ScFv5R induction dramatically decreased the activity
of Cdk2 to 20% of that observed in control cells. The
level of c-Myc and the D-cyclins, proteins involved in
p27 sequestration, also decreased in the absence of func-
tional HER2, freeing a pool of uncomplexed p27, which
is able to bind and inhibit cyclin E Cdk2 [24].
Reversal of malignant growth by anti-HER2 antibodies
The underlying mechanisms that mediate the anti-
tumor effects of anti-HER2 monoclonal antibodies are
not completely understood, but there are several proposed
mechanisms. Treatment of cancer cells overexpressing
HER2 with monoclonal antibodies results in a marked
downregulation of HER2 expression [25, 26]. This anti-
body-induced downregulation of HER2 has been shown
to induce reversion of the transformed phenotype in
«ew-transformed cells (neu is the rat HER2 equivalent)
[13]. A relationship between accelerated receptor endo-
cytosis and degradation, and anti-tumor effects of anti-
HER2 monoclonal antibodies is supported by correlative
in vitro studies with a range of monoclonal antibodies
[27]. Another property of some of these antibodies is
their partial ability to disrupt the formation of HER2-
HER3 and HER2-HER4 heterodimers [27, 28]. Possible
additional in vivo mechanisms of action may be caused
by an anti-angiogenic activity with downregulation of
vascular endothelial growth factor and other angiogenic
factors [29]. Furthermore, results from our laboratory
suggest that monoclonal antibodies inhibit the signaling
potential of overexpressed, oncogenic HER2 [30].
We have been studying the molecular effects of
monoclonal antibody 4D5, the murine precursor to
trastuzumab, on the BT-474 HER2-positive breast tumor
cells in order to understand the mechanism of action of
this growth inhibitory antibody. Furthermore, despite
the fact that trastuzumab has shown clinical success,
not all patients whose tumors overexpress HER2 respond
to this treatment. In order to elucidate the cause of non-
response, we have included in our studies the MKN7
gastric carcinoma tumor cells which overexpress HER2
but are not growth inhibited by 4D5.
Both BT-474 and MKN7 cells were treated with 4D5
and its effects on HER2 activity and the activity of
intracellular signaling proteins were measured. Surpris-
ingly, 4D5 treatment led to a rapid (10-minute) down-
regulation of the phosphotyrosine content and activity
of HER2 in both the responder and the non-responder
cell line. However, in the BT-474 cells, but not in the
MKN7 cells, a concomitant decrease in the activity of
the PI3K pathway, as measured by PKB activity, was
observed [30]. Furthermore, an examination of the HER
receptor profile in these two cell lines revealed that only
the BT-474 cells have high levels of active HER3. In
contrast, the MKN7 cells have high levels of active
HER 1/EGF receptor.
A model has been developed to demonstrate the
difference between these two cell lines (Figure 4). In
BT-474 cells, the HER2-HER3 heterodimer is very
important for maintaining high signaling activity. Treat-
ment with 4D5 affects activity of both HER2 and HER3
receptors because HER3 is dependent upon HER2 for
its activity. There is a dramatic decrease in PKB and
MAP kinase activity and the cells no longer proliferate.
In MKN7 cells, 4D5 treatment leads to a decrease in
phosphotyrosine content of HER2, but has no effect on
signaling pathways because these cells have a high level
of EGF receptor (HER1), which is unaffected by 4D5
treatment. This suggests that the response of a patient
to trastuzumab may not only be dependent on over-
expressed HER2, but may also be influenced by other
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Figure 4. Reversal of malignant growth by 4D5 (for explanation see text).
members of the HER receptor family, which are ex-
pressed in the tumor cell.
Conclusions
Amplification of the HER2 gene which leads to over-
expression of the HER2 receptor has a crucial role in the
transformation of cells. Overexpressed HER2 receptor,
combined preferentially with the HER3 receptor, sustains
overactivity of cell-signaling networks leading to high
levels of cell cycle regulators. This causes uncontrolled
cell growth, proliferation and tumorigenesis. In contrast,
functional inactivation of HER2 restrains cell growth
and proliferation.
Its crucial role in the development of tumors makes
HER2 a valid target for new anti-cancer treatments.
Monoclonal antibodies directed against the HER2 re-
ceptor are currently the most promising approach. The
recombinant human anti-HER2 monoclonal antibody,
trastuzumab, has been effective in phase II and III
clinical trials of women with HER2-positive metastatic
breast cancer either as first-line therapy or in patients
who had failed or relapsed after previous extensive treat-
ment with chemotherapy [31-33]. The mechanism of
action of growth inhibitory monoclonal antibodies tar-
geted to HER2 is not fully understood and seems to be
more complex than a simple downregulation of HER2
levels, as proposed from earlier studies. Some patients
with HER2-positive tumors do not respond to mono-
clonal antibodies, suggesting the involvement of factors
additional to HER2 overexpression. Studies in different
cell lines indicate that the response of a patient to
trastuzumab may not only be dependent on overex-
pressed HER2, but may also be influenced by expression
of other members of the HER receptor family in the
tumor cell.
The incidence of breast cancer has been increasing
steadily and is now the most common malignancy and
the second most common cause of cancer-related death
in European and North American women [34]. How-
ever, marked progress has been made in treating this
disease. The biologic behavior of this cancer, risk factors
and prognostic factors have been better characterized.
Several genetic abnormalities that are associated with
the development of breast cancer and/or correlated with
prognosis and response to treatment have been identified.
Recognition and understanding of the role of HER2 in
tumor development is allowing the development of new
and more effective treatments for this disease.
Note
The authors have not reported any financial relationships with compa-
nies whose products are mentioned in the text.
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